RA PHARMACEUTICALS, INC.
RA PHARMACEUTICALS, INC. (RARX): 8 pipeline candidates · ~21 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
21.3 months
D/E 0.08 · 0% dilution
Lead: Approved
8 candidates
N/A
N/A
A transparent, data-derived signal for RA PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$266.3M
Quarterly Burn
$37.8M
Runway
21.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| dapagliflozin | Approved |
| nintedanib | Approved |
| non-complement cardiovascular target candidate | Preclinical |
| oral small molecule c5 inhibitor | Preclinical |
| ra101495 sc | Phase 2 |
| xh-s003 | Phase 1 |
| zilucoplan | Phase 3 |
| zilucoplan xr | Phase 3 |
Frequently asked questions
How many drug candidates are in RA PHARMACEUTICALS, INC.'s pipeline?
RA PHARMACEUTICALS, INC. (RARX) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is RA PHARMACEUTICALS, INC.'s lead drug candidate?
RA PHARMACEUTICALS, INC.'s most advanced tracked candidate is dapagliflozin (Approved).
What is RA PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, RA PHARMACEUTICALS, INC. has approximately 21.3 months of cash runway.
Who is the CEO of RA PHARMACEUTICALS, INC.?
Contents Ra Pharmaceuticals is the chief executive officer of RA PHARMACEUTICALS, INC. (RARX).
Get the full picture on RA PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.